Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 May;73(10):1227–1232. doi: 10.1038/bjc.1996.235

Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.

M Takada 1, Y Kusunoki 1, N Masuda 1, K Matui 1, T Yana 1, S Ushijima 1, K Iida 1, K Tamura 1, T Komiya 1, I Kawase 1, N Kikui 1, H Morino 1, M Fukuoka 1
PMCID: PMC2074511  PMID: 8630283

Abstract

We attempted to clarify whether serum levels of a carboxy-terminal fragment of ProGRP, ProGRP(31-98), could serve as a more accurate tumour marker in patients with SCLC than neuron-specific enolase (NSE). ProGRP(31-98) and NSE were measured retrospectively in 101 newly diagnosed untreated patients with SCLC, 111 with non-small-cell lung cancer (NSCLC) and 114 patients with non-malignant lung diseases. ProGRP(31-98) and NSE levels were determined using a sandwich enzyme-linked immunosorbent assay. Sensitivity in SCLC patients was 72.3% for ProGRP(31-98) and 62.4% for NSE. Comparing the area under curve (AUC) of 'receiver operator characteristics' of ProGRP(31-98) with that of NSE, ProGRP(31-98) was the more powerful marker in the diagnosis of SCLC (P = 0.0001). Serum levels of ProGRP(31-98) were higher in the 40 patients with extensive disease than in the 61 patients with limited disease (P = 0.0082). ProGRP(31-98) was significantly higher in patients with pure small-cell carcinoma than in patients with mixed small-cell/large-cell carcinoma (P = 0.02). In serial measurement in 16 patients responding to treatment, a high degree of correlation was noted between the decrease in serum ProGRP(31-98) levels and clinical response during the second week after treatment (P = 0.0045). These results indicate that the determination of serum ProGRP(31-98) levels plays an important role in the diagnosis and treatment of SCLC patients.

Full text

PDF
1231

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akoun G. M., Scarna H. M., Milleron B. J., Bénichou M. P., Herman D. P. Serum neuron-specific enolase. A marker for disease extent and response to therapy for small-cell lung cancer. Chest. 1985 Jan;87(1):39–43. doi: 10.1378/chest.87.1.39. [DOI] [PubMed] [Google Scholar]
  2. Aoyagi K., Miyake Y., Urakami K., Kashiwakuma T., Hasegawa A., Kodama T., Yamaguchi K. Enzyme immunoassay of immunoreactive progastrin-releasing peptide(31-98) as tumor marker for small-cell lung carcinoma: development and evaluation. Clin Chem. 1995 Apr;41(4):537–543. [PubMed] [Google Scholar]
  3. Ariyoshi Y., Kato K., Ishiguro Y., Ota K., Sato T., Suchi T. Evaluation of serum neuron-specific enolase as a tumor marker for carcinoma of the lung. Gan. 1983 Apr;74(2):219–225. [PubMed] [Google Scholar]
  4. Bates S. E., Longo D. L. Use of serum tumor markers in cancer diagnosis and management. Semin Oncol. 1987 Jun;14(2):102–138. [PubMed] [Google Scholar]
  5. Carney D. N., Gazdar A. F., Bepler G., Guccion J. G., Marangos P. J., Moody T. W., Zweig M. H., Minna J. D. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 1985 Jun;45(6):2913–2923. [PubMed] [Google Scholar]
  6. Carney D. N., Marangos P. J., Ihde D. C., Bunn P. A., Jr, Cohen M. H., Minna J. D., Gazdar A. F. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet. 1982 Mar 13;1(8272):583–585. doi: 10.1016/s0140-6736(82)91748-2. [DOI] [PubMed] [Google Scholar]
  7. Cooper E. H., Splinter T. A., Brown D. A., Muers M. F., Peake M. D., Pearson S. L. Evaluation of a radioimmunoassay for neuron specific enolase in small cell lung cancer. Br J Cancer. 1985 Sep;52(3):333–338. doi: 10.1038/bjc.1985.198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cuttitta F., Fedorko J., Gu J. A., Lebacq-Verheyden A. M., Linnoila R. I., Battey J. F. Gastrin-releasing peptide gene-associated peptides are expressed in normal human fetal lung and small cell lung cancer: a novel peptide family found in man. J Clin Endocrinol Metab. 1988 Sep;67(3):576–583. doi: 10.1210/jcem-67-3-576. [DOI] [PubMed] [Google Scholar]
  9. Erisman M. D., Linnoila R. I., Hernandez O., DiAugustine R. P., Lazarus L. H. Human lung small-cell carcinoma contains bombesin. Proc Natl Acad Sci U S A. 1982 Apr;79(7):2379–2383. doi: 10.1073/pnas.79.7.2379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Esscher T., Steinholtz L., Bergh J., Nöu E., Nilsson K., Påhlman S. Neurone specific enolase: a useful diagnostic serum marker for small cell carcinoma of the lung. Thorax. 1985 Feb;40(2):85–90. doi: 10.1136/thx.40.2.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fukuoka M., Furuse K., Saijo N., Nishiwaki Y., Ikegami H., Tamura T., Shimoyama M., Suemasu K. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991 Jun 19;83(12):855–861. doi: 10.1093/jnci/83.12.855. [DOI] [PubMed] [Google Scholar]
  12. Hirsch F. R., Matthews M. J., Aisner S., Campobasso O., Elema J. D., Gazdar A. F., Mackay B., Nasiell M., Shimosato Y., Steele R. H. Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer. 1988 Sep 1;62(5):973–977. doi: 10.1002/1097-0142(19880901)62:5<973::aid-cncr2820620521>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  13. Holst J. J., Hansen M., Bork E., Schwartz T. W. Elevated plasma concentrations of C-flanking gastrin-releasing peptide in small-cell lung cancer. J Clin Oncol. 1989 Dec;7(12):1831–1838. doi: 10.1200/JCO.1989.7.12.1831. [DOI] [PubMed] [Google Scholar]
  14. Ishiguro Y., Kato K., Shimizu A., Ito T., Nagaya M. High levels of immunoreactive nervous system-specific enolase in sera of patients with neuroblastoma. Clin Chim Acta. 1982 May 20;121(2):173–180. doi: 10.1016/0009-8981(82)90056-0. [DOI] [PubMed] [Google Scholar]
  15. Knigge U., Holst J. J., Knuhtsen S., Petersen B., Krarup T., Holst-Pedersen J., Christiansen P. M. Gastrin-releasing peptide: pharmacokinetics and effects on gastro-entero-pancreatic hormones and gastric secretion in normal men. J Clin Endocrinol Metab. 1984 Aug;59(2):310–315. doi: 10.1210/jcem-59-2-310. [DOI] [PubMed] [Google Scholar]
  16. Masuda N., Fukuoka M., Kusunoki Y., Matsui K., Takifuji N., Kudoh S., Negoro S., Nishioka M., Nakagawa K., Takada M. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992 Aug;10(8):1225–1229. doi: 10.1200/JCO.1992.10.8.1225. [DOI] [PubMed] [Google Scholar]
  17. McDonald T. J., Nilsson G., Vagne M., Ghatei M., Bloom S. R., Mutt V. A gastrin releasing peptide from the porcine nonantral gastric tissue. Gut. 1978 Sep;19(9):767–774. doi: 10.1136/gut.19.9.767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. McKenzie C. G., Evans I. M., Hillyard C. J., Hill P., Carter S., Tan M. K., MacIntyre I. Biochemical markers in bronchial carcinoma. Br J Cancer. 1977 Dec;36(6):700–707. doi: 10.1038/bjc.1977.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  20. Miyake Y., Kodama T., Yamaguchi K. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res. 1994 Apr 15;54(8):2136–2140. [PubMed] [Google Scholar]
  21. Moody T. W., Pert C. B., Gazdar A. F., Carney D. N., Minna J. D. High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science. 1981 Dec 11;214(4526):1246–1248. doi: 10.1126/science.6272398. [DOI] [PubMed] [Google Scholar]
  22. Mountain C. F. A new international staging system for lung cancer. Chest. 1986 Apr;89(4 Suppl):225S–233S. doi: 10.1378/chest.89.4_supplement.225s. [DOI] [PubMed] [Google Scholar]
  23. Murray N., Shah A., Osoba D., Page R., Karsai H., Grafton C., Goddard K., Fairey R., Voss N. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol. 1991 Sep;9(9):1632–1638. doi: 10.1200/JCO.1991.9.9.1632. [DOI] [PubMed] [Google Scholar]
  24. Notomi T., Morikawa J., Kato K., Tsuchida Y., Ohsawa R. Radioimmunoassay development for human neuron-specific enolase: with some clinical results in lung cancers and neuroblastoma. Tumour Biol. 1985;6(1):57–66. [PubMed] [Google Scholar]
  25. Nõu E., Steinholtz L., Bergh J., Nilsson K., Påhlman S. Neuron-specific enolase as a follow-up marker in small cell bronchial carcinoma. A prospective study in an unselected series. Cancer. 1990 Mar 15;65(6):1380–1385. doi: 10.1002/1097-0142(19900315)65:6<1380::aid-cncr2820650622>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  26. Spindel E. R., Chin W. W., Price J., Rees L. H., Besser G. M., Habener J. F. Cloning and characterization of cDNAs encoding human gastrin-releasing peptide. Proc Natl Acad Sci U S A. 1984 Sep;81(18):5699–5703. doi: 10.1073/pnas.81.18.5699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wharton J., Polak J. M., Bloom S. R., Ghatei M. A., Solcia E., Brown M. R., Pearse A. G. Bombesin-like immunoreactivity in the lung. Nature. 1978 Jun 29;273(5665):769–770. doi: 10.1038/273769a0. [DOI] [PubMed] [Google Scholar]
  28. Yamaguchi K., Abe K., Kameya T., Adachi I., Taguchi S., Otsubo K., Yanaihara N. Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res. 1983 Aug;43(8):3932–3939. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES